Evoxia Labs

A clear-eyed look at where they stood.

Evoxia Labs is a DPIIT-recognised startup working in sustainable materials and biopolymers, at seed stage. The company had proven its material at prototype scale and needed capital to take the next step: pilot manufacturing. That step typically means process equipment, batch trials at larger volumes, and material testing that a lab-scale prototype never has to survive. It is capital-intensive in a way that early prototyping is not.

For a materials startup at this stage, non-dilutive capital is the preferred route. Giving up equity to fund a pilot batch, before the process is even proven at scale, is an expensive way to raise money that a founder would rather not repeat later at a real Series A. SISFS exists for exactly this gap, but it is not a single, undifferentiated pool of money.

The scheme runs two separate routes: a grant of up to ₹20 lakh, or a convertible-debenture instrument of up to ₹50 lakh. A startup gets one or the other, never both, and the two ceilings are not additive. Which route an incubator committee sanctions depends on how the application itself is built.

CapEasy structured the SISFS proposal specifically for the convertible-debenture route, rather than adapting a grant-style application after the fact. That meant building the eligibility case, a utilisation plan that stayed within what the scheme permits, and the milestone and financial framing that a debt-linked instrument requires, from the ground up for that tier.

The two SISFS routes are not evaluated the same way. A grant application can lean on the underlying innovation. A convertible-debenture application at the higher ceiling has to additionally satisfy an incubator committee that the money will convert into a specific, financeable use: equipment, trial runs, working capital tied to a pilot-scale plan with numbers attached, rather than a research narrative alone.

CapEasy’s work was to position Evoxia Labs’ application to be read against that debt-instrument standard from the first draft, so the committee was evaluating a complete case for the ₹50 lakh tier rather than a grant application asked to stretch further.

SISFS committees generally press hardest on the use-of-funds plan: what each rupee is for, over what timeline, and how progress will be checked. A plan that reads as generic or unbudgeted is the most common reason an application gets pushed down to a smaller ask or sent back for revision.

The outcome

The application was approved for a ₹50 lakh SISFS convertible debenture through the AIC-GUSEC incubator, at the higher tier CapEasy had built the case for.

A Seed Fund approval is the incubator committee’s sanction, not the money itself. Disbursement is milestone-released and follows the scheme’s own due-diligence and compliance requirements at each stage; it is not automatic and outcomes vary case to case.

What made it work

The deciding factor was matching the application to the instrument being sought, not the instrument being convenient to write about. A convertible-debenture case at the ₹50 lakh ceiling needs a different depth of financial and milestone detail than a ₹20 lakh grant case, and building for that standard from the start is what let the committee sanction the higher tier rather than negotiate it down.

Milestone-released disbursement also means the utilisation plan has to hold up stage by stage, past the point of initial approval. Framing it that way at the application stage gives both the incubator and the startup a shared, checkable basis for each release, rather than a single number that has to be re-justified later.